Screener
CG Oncology CGON EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's EPS (diluted)?
- CG Oncology (CGON) reported EPS (diluted) of -$0.90 in Q2 2026.
- How has CG Oncology's EPS (diluted) changed year-over-year?
- CG Oncology's EPS (diluted) decreased by 66.7% year-over-year, from -$0.54 to -$0.90.
- What is the long-term trend for CG Oncology's EPS (diluted)?
- Over 2 years (2023 to 2025), CG Oncology's EPS (diluted) has grown at a -63.6% compound annual growth rate (CAGR), from -$15.62 to -$2.07.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about CG Oncology's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude